Free Trial

Sera Prognostics Q1 2024 Earnings Report

Sera Prognostics logo
$6.64 +0.22 (+3.43%)
As of 04:00 PM Eastern

Sera Prognostics EPS Results

Actual EPS
-$0.25
Consensus EPS
-$0.23
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Sera Prognostics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sera Prognostics Announcement Details

Quarter
Q1 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Sera Prognostics Earnings Headlines

URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More Sera Prognostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sera Prognostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sera Prognostics and other key companies, straight to your email.

About Sera Prognostics

Sera Prognostics (NASDAQ:SERA), a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

View Sera Prognostics Profile

More Earnings Resources from MarketBeat